Dynacure’s Antisense Approach To Rare Myopathies Gets Funding Boost
Ionis Collaborating On Development
France’s fledgling biotech Dynacure has pulled together a series C funding round to support its ongoing Phase I/II study of an antisense molecule for an ultrarare myopathy.
